Krka, d. d. (BUL:KN8)

Market Cap	7.55B +22.4%
Revenue (ttm)	2.17B +7.9%
Net Income	444.52M +11.5%
EPS	14.66 +12.6%
Shares Out	n/a
PE Ratio	17.02
Forward PE	16.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	246.50
Day's Range	n/a
52-Week Range	242.50 - 250.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Krka, d. d.

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, and other therapeutic areas. It also provides non-prescription products for cough, cold, cerebral, peripheral circulation, gastrointestinal tract, metabo...

• Industry: Pharmaceutical Preparations
• Founded: 1954
• Employees: 13,300
• Stock Exchange: Bulgarian Stock Exchange
• Ticker Symbol: KN8

Financial Performance

In 2025, Krka, d. d.'s revenue was 2.04 billion, an increase of 6.89% compared to the previous year's 1.91 billion. Earnings were 403.24 million, an increase of 12.96%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 13, 2026

Data Sources Report a data error